Categories
Change Password!
Reset Password!
Subcutaneous Abaloparatide led to rapid and significant improvements in bone mineral density at the lumbar spine, total hip, and femoral neck in males with osteoporosis.
The findings of a recent randomized clinical trial suggested that the use of Abaloparatide for 12 months can be considered an efficient, safe, and well-tolerated anabolic therapeutic option for males suffering from osteoporosis. Investigators wanted to compare Abaloparatide to placebo in terms of effectiveness and safety to treat osteoporosis. Men (40-85 years old) with osteoporosis who were eligible were randomly assigned 2:1 to receive Abaloparatide 80 μg subcutaneously every day or placebo for 12 months.
Alteration from baseline in lumbar spine bone mineral density (BMD) was the major outcome. BMD changes from baseline at the whole hip and femoral neck were important secondary outcomes ascertained. Overall, 228 males were randomly assigned to Abaloparatide [n = 149] and placebo [n = 79]. The baseline parameters (mean age, 68.3 years; mean lumbar spine BMD T-score, -2.1) were comparable between treatment groups.
Abaloparatide resulted in larger BMD increases in the lumbar spine (least squares mean percentage alteration [standard error]: 8.48 [0.54] vs 1.17 [0.72]), femoral neck (2.98 [0.34] vs. 0.15 [0.45]), and total hip (2.14 [0.27] vs. 0.01 [0.35]) at 12 months when contrasted to placebo. Headache, hypertension, bronchitis, arthralgia, nasopharyngitis, dizziness, and injection site reaction were the most frequent (≥5%) treatment-emergent adverse events.
Men with osteoporosis experienced quick and considerable enhancements in BMD throughout the course of a 12-month Abaloparatide therapy, with a safety profile that was similar to trials carried out previously. Therefore, Abaloparatide is a viable anabolic therapy option for males with osteoporosis.
Journal of Bone and Mineral Research
The Efficacy and Safety of Abaloparatide-SC in Men with Osteoporosis: A Randomized Clinical Trial
Edward Czerwinski et al.
Comments (0)